S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
NASDAQ:PODD

Insulet (PODD) Stock Forecast, Price & News

$196.91
-2.15 (-1.08%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$195.59
$206.23
50-Day Range
$186.40
$279.02
52-Week Range
$181.00
$324.81
Volume
328,959 shs
Average Volume
615,204 shs
Market Capitalization
$13.65 billion
P/E Ratio
312.56
Dividend Yield
N/A
Beta
0.72
30 days | 90 days | 365 days | Advanced Chart
Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Insulet logo

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.06 per share
Book Value
$8.07 per share

Profitability

Net Income
$16.80 million
Pretax Margin
4.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
68,716,000
Market Cap
$13.65 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/16/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

420th out of 1,423 stocks

Surgical & Medical Instruments Industry

52nd out of 138 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -













Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.17. The medical instruments supplier had revenue of $295.40 million for the quarter, compared to analysts' expectations of $287.99 million. Insulet had a trailing twelve-month return on equity of 15.81% and a net margin of 3.91%. Insulet's quarterly revenue was up 17.1% compared to the same quarter last year.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

What price target have analysts set for PODD?

11 brokerages have issued twelve-month price targets for Insulet's stock. Their forecasts range from $230.00 to $350.00. On average, they anticipate Insulet's stock price to reach $302.33 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?
Insulet's management team includes the following people:
What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.95%), Clearbridge Investments LLC (2.45%), Primecap Management Co. CA (1.78%), Echo Street Capital Management LLC (1.16%), Goldman Sachs Group Inc. (0.85%) and Viking Global Investors LP (0.79%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Eric Benjamin, John A Fallon, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Viking Global Investors LP, Sumitomo Mitsui Trust Holdings Inc., Bank of Nova Scotia, Frontier Capital Management Co. LLC, Bank of New York Mellon Corp, Scout Investments Inc., and Loomis Sayles & Co. L P. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, Shacey Petrovic, and Wayde D Mcmillan.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Clearbridge Investments LLC, Echo Street Capital Management LLC, Ownership Capital B.V., Renaissance Technologies LLC, Blair William & Co. IL, Jag Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $196.91.

How much money does Insulet make?

Insulet has a market capitalization of $13.65 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.